From: The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese
HCV-1 | HCV-2 | ||||||||
---|---|---|---|---|---|---|---|---|---|
SNP ID | SVR (+) | SVR (−) | P | OR (95% CI) | SNP ID | SVR (+) | SVR (−) | P | OR (95% CI) |
N (%) | N (%) | N (%) | N (%) | ||||||
rs1059513 | rs1059513 | ||||||||
A/A | 131 (80.4) | 93 (91.2) | 0.40 (0.18, 0.87) | A/A | 155 (87.1) | 15 (88.2) | 0.90 (0.19, 4.19) | ||
A/G | 32 (19.6) | 9 (8.8) | 0.0179* | 1 | A/G | 23 (12.9) | 2 (11.8) | 0.8916 | 1 |
G/G | 0 (0.0) | 0 (0.0) | - | - | G/G | 0 (0.0) | 0 (0.0) | - | - |
A/A + A/G | 163 (100.0) | 102 (100.0) | - | - | A/A + A/G | 178 (100.0) | 17 (100.0) | - | - |
rs703817 a | rs703817 | ||||||||
A/A | 11 (6.7) | 9 (8.9) | 0.61 (0.24, 1.58) | A/A | 11 (6.2) | 0 (0.0) | - | ||
A/G | 58 (35.6) | 45 (44.6) | 0.64 (0.38, 1.09) | A/G | 71 (39.9) | 5 (29.4) | 1.78 (0.60, 5.27) | ||
G/G | 94 (57.7) | 47 (46.5) | 0.2103 | 1 | G/G | 96 (53.9) | 12 (70.6) | 0.3223 | 1 |
A/A + A/G | 69 (42.3) | 54 (53.5) | 0.0780 | 0.64 (0.39, 1.05) | A/A + A/G | 82 (46.1) | 5 (29.4) | 0.1869 | 2.05 (0.69, 6.06) |
rs324015 a | rs324015 | ||||||||
A/A | 34 (20.9) | 20 (19.8) | 1.05 (0.52, 2.12) | A/A | 39 (21.9) | 6 (35.3) | 0.43 (0.10, 1.85) | ||
A/G | 77 (47.2) | 49 (48.5) | 0.97 (0.55, 1.71) | A/G | 94 (52.8) | 8 (47.1) | 0.78 (0.20, 3.09) | ||
G/G | 52 (31.9) | 32 (31.7) | 0.9723 | 1 | G/G | 45 (25.3) | 3 (17.6) | 0.4339 | 1 |
A/A + A/G | 111 (68.1) | 69 (68.3) | 0.9704 | 0.99 (0.58, 1.69) | A/A + A/G | 133 (74.7) | 14 (82.4) | 0.4851 | 0.63 (0.17, 2.31) |
rs3024974 | rs3024974 b | ||||||||
C/C | 105 (64.4) | 61 (59.8) | 0.34 (0.07, 1.62) | C/C | 113 (63.9) | 11 (64.7) | 2.05 (0.22, 19.19) | ||
C/T | 48 (29.5) | 39 (38.2) | 0.25 (0.05, 1.19) | C/T | 59 (33.3) | 5 (29.4) | 2.36 (0.23, 24.33) | ||
T/T | 10 (6.1) | 2 (2.0) | 0.1285 | 1 | T/T | 5 (2.8) | 1 (5.9) | 0.7623 | 1 |
C/C + C/T | 153 (93.9) | 100 (98.0) | 0.1118 | 0.31 (0.07, 1.43) | C/C + C/T | 172 (97.2) | 16 (94.1) | 0.4867 | 2.15 (0.24, 19.55) |